arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Karyopharm Therapeutics Inc.

KPTI
$2.10 ▲ +0.17 (+8.51%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
57 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
44
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Karyopharm Therapeutics Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap
Dividend Yield
Revenue Growth 16.8%
Op. Margin -76.3%
ROIC 10.1%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

57-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$35.07M
↑ +16.8%
Net Income Profit after all expenses
$-22.39M
↑ +4.6%
Operating Margin Operating profit as % of sales
-76.3%
↓ -45.7% 4th
FCF / Share Free cash flow per share
$-0.38
↓ -128.3%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
98
Financial Health
32
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 57 quarters